The effect of glucagon-like peptide 1 on cardiovascular risk

被引：0
|
作者：
Jacob Sivertsen
Jaya Rosenmeier
Jens J. Holst
Tina Vilsbøll
机构：
[1] Gentofte Hospital,Department of Cardiology
[2] University of Copenhagen,Diabetes Research Division, Department of Internal Medicine
[3] Gentofte Hospital,Department of Biomedical Sciences
[4] University of Copenhagen,undefined
[5] The NovoNordisk Foundation Center for Basic Metabolic Research,undefined
[6] The Panum Institute,undefined
[7] University of Copenhagen,undefined
来源：
Nature Reviews Cardiology | 2012年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Glucagon-like peptide 1 (GLP)-based therapies reduce blood glucose levels in patients with type 2 diabetes mellitus. Interestingly, GLP 1 receptor agonists can also have beneficial effects on cardiovascular risk. Dr. Sivertsen and colleagues provide an overview of the cardiovascular mechanisms targeted by GLP 1-based therapies and discuss clinical data for long-term management of cardiovascular risk in patients treated with these agents.
引用
收藏
页码：209 / 222
页数：13
相关论文
共 50 条
  • [1] The effect of glucagon-like peptide 1 on cardiovascular risk
    Sivertsen, Jacob
    Rosenmeier, Jaya
    Holst, Jens J.
    Vilsboll, Tina
    NATURE REVIEWS CARDIOLOGY, 2012, 9 (04) : 209 - 222
  • [2] Cardiovascular Effects of Glucagon-Like Peptide 1
    Papazafiropoulou, A.
    Pappas, S. I.
    Papadogiannis, D.
    Tentolouris, N.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2011, 11 (01) : 97 - 105
  • [3] Glucagon-Like Peptide 1 and the Cardiovascular System
    Fava, Stephen
    CURRENT DIABETES REVIEWS, 2014, 10 (05) : 302 - 310
  • [4] Effects of glucagon-like peptide-1 on cardiovascular risk factors and cardiovascular system
    Fiorentino, Teresa Vanessa
    Sesti, Giorgio
    GIORNALE ITALIANO DI CARDIOLOGIA, 2016, 17 (12) : 13S - 19S
  • [5] The Cardiovascular Biology of Glucagon-like Peptide-1
    Drucker, Daniel J.
    CELL METABOLISM, 2016, 24 (01) : 15 - 30
  • [6] Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
    Mannucci, E.
    Rotella, C. M.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2008, 18 (09) : 639 - 645
  • [7] EFFECT OF GLUCAGON ON SECRETION OF GLUCAGON-LIKE PEPTIDE-1
    SHIMA, K
    OHBOSHI, C
    SATO, M
    HIROTA, M
    HORMONE AND METABOLIC RESEARCH, 1988, 20 (02) : 123 - 124
  • [8] Glucagon-like peptide-1 and glucagon-like peptide-2
    Baggio, LL
    Drucker, DJ
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 18 (04) : 531 - 554
  • [9] Cardiovascular and hemodynamic effects of glucagon-like peptide-1
    Adam G. Goodwill
    Kieren J. Mather
    Abass M. Conteh
    Daniel J. Sassoon
    Jillian N. Noblet
    Johnathan D. Tune
    Reviews in Endocrine and Metabolic Disorders, 2014, 15 : 209 - 217
  • [10] Glucagon-Like Peptide-1 and its Cardiovascular Effects
    Heo, Kyung-Sun
    Fujiwara, Keigi
    Abe, Jun-ichi
    CURRENT ATHEROSCLEROSIS REPORTS, 2012, 14 (05) : 422 - 428
12345